Trial Profile
A Fifty-Two-Week Multicenter, Open-Label, Study Evaluating the Long-Term Safety and Tolerability of SR58611A 350 mg q12 in Patients With Major Depressive Disorder
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Apr 2022
Price :
$35
*
At a glance
- Drugs Amibegron (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions; Registrational
- Sponsors Sanofi
- 05 Mar 2009 New trial record